Category Archives: Blog / News

Promethera Biosciences successfully enrolls twenty patients in its multicentric Phase I/II trial
13.11.2013

Promethera Biosciences has conducted the trial in Belgium, France, United …

Continue reading

Job Offer : ITEOS Therapeutics is looking for Research Scientist
25.03.2013

We are looking for: Iteos Position Research Scientist March 2013 (full-time …

Continue reading

SORIN Acquires UCL Spin-off NeuroTECH
22.02.2013

Louvain-la-Neuve, Belgium- November 12th, 2012 – SORIN, a global medical …

Continue reading

MSC Software Acquires UCL Spin-off e-Xstream

Louvain-la-Neuve, Belgium- September 27th, 2012 – MSC Software, one of …

Continue reading

Sopartec is looking for a CEO with a strong track record in the biotech industry
06.07.2012

For the creation of a new spin-off company based on the development of novel cell-based therapies, SOPARTEC SA (www.sopartec.com), Member of the Louvain Technology Transfer Office, is looking for A CHIEF EXECUTIVE OFFICER with a strong track record in the biotech/biomedical industry

Continue reading

Neurotech s.a. Announces European CE Mark Approval for the ADNS-300 System to Treat Refractory Epilepsy.
19.06.2012

Louvain la Neuve, Belgium, June 5, 2012 —Neurotech s.a. (www.neurotech-int.eu) a Belgium based developer and manufacturer of neurostimulation devices, announces that it has obtained the European CE Mark for its ADNS-300 system dedicated to the treatment of refractory epilepsy. The surgically implanted ADNS-300 system delivers mild electrical pulses to the vagus nerve in the neck. Operating as a pacemaker, it produces stimulation towards the brain.

Continue reading

Promethera Biosciences treats first patients with Promethera® HepaStem
14.05.2012

Mont-Saint-Guibert, Belgium, May 14 2012 – Promethera Biosciences, a Belgian biotechnology Company developing Promethera® HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, today announces it has treated its first two patients with its innovative treatment based on allogeneic adult liver stem cell technology (HepaStem). These patients were treated and are followed at the Cliniques
Universitaires Saint-Luc (Brussels, Belgium).

Continue reading

Vives subscribes to a € 6 million capital increase to support GreenWatt growth
20.04.2012

Vives – Louvain Technology Fund subscribes jointly with historic shareholders and new investors Gimv Agri+, RWE Innogy Ventures and SRIW to a € 6 million capital increase of GreenWatt S.A.
With this capital increase, GreenWatt S.A. will accelerate its international development in the waste-to-energy business.

Continue reading

Launch of VivesII, the largest european university technology fund
28.09.2011

Louvain-la-Neuve, 28 September 2011 – The Université catholique de Louvain (UCL) and Sopartec, its technology transfer
company, today announced the launch of Vives II. The first financing round, which brings together a dozen investors,
amounts to €43 million, making Vives II the largest European investment fund ever initiated by a university.

Click on the link below to download our press release in a PDF format.

Press release in a PDF format

Continue reading

More news